Based on the OraSure Technologies Inc stock forecast from 1 analysts, the average analyst target price for OraSure Technologies Inc is USD 4.00 over the next 12 months. OraSure Technologies Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of OraSure Technologies Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, OraSure Technologies Inc’s stock price was USD 3.11. OraSure Technologies Inc’s stock price has changed by -9.33% over the past week, -4.31% over the past month and -47.82% over the last year.
No recent analyst target price found for OraSure Technologies Inc
No recent average analyst rating found for OraSure Technologies Inc
Company Overview OraSure Technologies Inc
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h Read Less
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products in...Read More
Frequently Asked Questions About OraSure Technologies Inc (OSUR) Stock
Based on ratings from 1 analysts OraSure Technologies Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on OSUR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for OSUR is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
OSUR stock's Price/Earning ratio is 26.80.
Our analysis grades OSUR stock's Price / Earning ratio at F. This means that OSUR stock's Price/Earning ratio is above 46% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this OSUR may be fairly valued for its sector
The last closing price of OSUR's stock was USD 3.11.
The most recent market capitalization for OSUR is USD 0.26B.
Based on targets from 1 analysts, the average taret price for OSUR is projected at USD 4.00 over the next 12 months.
This means that OSUR's stock price may go up by +28.62% over the next 12 months.
We can't find any ETFs which contains OraSure Technologies Inc's stock.
As per our most recent records OraSure Technologies Inc has 501 Employees.
OraSure Technologies Inc's registered address is 220 East First Street, Bethlehem, PA, United States, 18015.
You can get more information about it from OraSure Technologies Inc's website at https://www.orasure.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About OraSure Technologies Inc (OSUR) Stock
Based on ratings from 1 analysts OraSure Technologies Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on OSUR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for OSUR is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
OSUR stock's Price/Earning ratio is 26.80.
Our analysis grades OSUR stock's Price / Earning ratio at F. This means that OSUR stock's Price/Earning ratio is above 46% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this OSUR may be fairly valued for its sector
The last closing price of OSUR's stock was USD 3.11.
The most recent market capitalization for OSUR is USD 0.26B.
Based on targets from 1 analysts, the average taret price for OSUR is projected at USD 4.00 over the next 12 months.
This means that OSUR's stock price may go up by +28.62% over the next 12 months.
We can't find any ETFs which contains OraSure Technologies Inc's stock.
As per our most recent records OraSure Technologies Inc has 501 Employees.
OraSure Technologies Inc's registered address is 220 East First Street, Bethlehem, PA, United States, 18015.
You can get more information about it from OraSure Technologies Inc's website at https://www.orasure.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OSUR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
